Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vyne Therapeutics Inc. (VYNE:NASDAQ), powered by AI.
Vyne Therapeutics Inc. is currently trading at $0.63. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Vyne Therapeutics Inc. on Alpha Lenz.
View Vyne Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Vyne Therapeutics Inc.'s ROE is -66.3%. Explore profitability and growth together.”
Ask for details →Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative dermatology solutions. Primarily focused on the treatment of skin diseases, Vyne Therapeutics leverages its proprietary technologies to address conditions such as acne and rosacea. The company's commitment to advancing dermatological research is evident in its pipeline of therapeutic products that aim to enhance the care and management of skin conditions. By working closely with healthcare professionals and leveraging partnerships within the pharmaceutical industry, Vyne Therapeutics strives to deliver effective treatment options that improve patient outcomes. As an active participant in the biopharmaceutical market, Vyne Therapeutics plays a critical role in advancing dermatological therapies, contributing to the broader medical and healthcare sectors by providing solutions that benefit consumers and practitioners alike.
“Vyne Therapeutics Inc.'s ROE is -66.3%. Explore profitability and growth together.”
Ask for details →Vyne Therapeutics Inc. (ticker: VYNE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees.
The current price is $0.633 with a P/E ratio of -x and P/B of -x.
ROE is -66.33% and operating margin is -5219.12%. Annual revenue is $570,000.